| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/18/2012 | EP2407556A1 Method for determining sensitivity to irinotecan and use thereof |
| 01/18/2012 | EP2407476A1 Steroid compound |
| 01/18/2012 | EP2407475A2 Synthetic Bile Acid Composition, Method, and Preparation |
| 01/18/2012 | EP2407474A1 Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fat |
| 01/18/2012 | EP2407473A2 Method for producing phosphorus-containing compounds |
| 01/18/2012 | EP2407471A2 Process for preparing a crystalline form of rapamycin analogs |
| 01/18/2012 | EP2407469A1 Salt of sitagliptin |
| 01/18/2012 | EP2407467A1 Crystalline compound of1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol and lactic acid |
| 01/18/2012 | EP2407466A1 Piperazine compound capable of inhibiting prostaglandin d synthase |
| 01/18/2012 | EP2407462A1 Substituted chroman derivatives, medicaments and use in therapy |
| 01/18/2012 | EP2407454A1 Prophylactic or therapeutic agent for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivative or salt thereof as active ingredient |
| 01/18/2012 | EP2407453A1 PGD2 receptor antagonist |
| 01/18/2012 | EP2407451A1 N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors |
| 01/18/2012 | EP2407204A1 Fluid medication delivery device |
| 01/18/2012 | EP2407179A1 External preparation containing analgesic/anti-inflammatory agent |
| 01/18/2012 | EP2407169A1 Combination formulations of anthracycline agents and cytidine analogs |
| 01/18/2012 | EP2407168A1 Use of dpp iv inhibitors |
| 01/18/2012 | EP2407167A2 Therapeutic agent for neurodegenerative disease |
| 01/18/2012 | EP2407166A1 Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
| 01/18/2012 | EP2407165A1 Antioxidant agent |
| 01/18/2012 | EP2407164A1 Copper II complexes of phenanthroline and their use in cancer treatment |
| 01/18/2012 | EP2407163A1 Compounds with a skin pigmenting activity and pharmaceutical or cosmetic compositions containing them |
| 01/18/2012 | EP2407162A1 Composition for oral administration |
| 01/18/2012 | EP2407161A1 An antitumoral combination comprising ombrabulin and bevacizumab |
| 01/18/2012 | EP2407160A1 Pharmaceutical composition for prevention and/or treatment of bone disease, functional food or health food comprising the composition, and pharmaceutical preparation comprising the composition as active ingredient |
| 01/18/2012 | EP2407159A1 Pharmaceutical compositions of olmesartan |
| 01/18/2012 | EP2407157A1 Lipid bilayer carrier for drugs or imaging agents |
| 01/18/2012 | EP2407153A1 Preparation method of carotenoid oil suspensions with low viscosity and high fluidity and its use |
| 01/18/2012 | EP2407151A1 Composition for the treatment of skin and/or nail lesions |
| 01/18/2012 | EP2407150A1 Polymer nano and micro particles for the maintenance of the low surface tension in the lung and for the protection of the pulmonary surfactant |
| 01/18/2012 | EP2407036A1 Method for stimulating intestinal barrier integrity after non-natural birth |
| 01/18/2012 | EP2406379A1 Compositions and methods for the delivery of biologically active rnas |
| 01/18/2012 | EP2406304A1 Gaba-linked anthracycline-lipid conjugates |
| 01/18/2012 | EP2406272A1 N-hydroxy c29-amide derivatives of oleandrane |
| 01/18/2012 | EP2406271A1 A novel crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| 01/18/2012 | EP2406266A1 7-cycloalkylaminoquinolones as gsk-3 inhibitors |
| 01/18/2012 | EP2406265A2 Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators |
| 01/18/2012 | EP2406263A1 Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof |
| 01/18/2012 | EP2406262A1 Prodrug forms of kinase inhibitors and their use in therapy |
| 01/18/2012 | EP2406261A1 10-amino-1,2,3,4-tetrahydropyrido[2,1-a]isoindol-6(10bh)-one derivatives, method for preparing same, and therapeutic uses thereof |
| 01/18/2012 | EP2406260A1 Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases |
| 01/18/2012 | EP2406259A1 Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases |
| 01/18/2012 | EP2406258A1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| 01/18/2012 | EP2406256A1 Compounds for the treatment of metabolic disorders |
| 01/18/2012 | EP2406255A1 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases |
| 01/18/2012 | EP2406253A1 Benzofuranyl derivatives used as glucokinase inhibitors |
| 01/18/2012 | EP2406252A1 Mineralocorticoid receptor antagonist and methods of use |
| 01/18/2012 | EP2406251A1 Compounds for the treatment of metabolic disorders |
| 01/18/2012 | EP2406250A1 Inhibitors of akt activity |
| 01/18/2012 | EP2406249A1 Indole derivatives as ikk2 inhibitors |
| 01/18/2012 | EP2406248A1 Novel isoindolin-1-one derivative |
| 01/18/2012 | EP2406247A1 Compounds for the treatment of metabolic disorders |
| 01/18/2012 | EP2406244A2 Estrogenic compounds and their methods of use |
| 01/18/2012 | EP2406243A1 Benzofuran derivatives |
| 01/18/2012 | EP2406240A2 Inhibitors of beta-secretase |
| 01/18/2012 | EP2406238A1 Metal ion chelating agents, methods for preparing same and uses thereof |
| 01/18/2012 | EP2406236A1 Rho kinase inhibitors |
| 01/18/2012 | EP2406235A2 Process for the preparation of bosentan |
| 01/18/2012 | EP2406230A1 Substituted indazole amides and their use as glucokinase activators |
| 01/18/2012 | EP2406229A1 Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators |
| 01/18/2012 | EP2406228A1 Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulators |
| 01/18/2012 | EP2406227A1 Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1- hydroxyethyl)-8-hydroxyquinolin-2(1h)-one. |
| 01/18/2012 | EP2406226A1 Substituted nicotinamides as kcnq2/3 modulators |
| 01/18/2012 | EP2406225A1 Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors |
| 01/18/2012 | EP2406224A1 Substituted 2-mercapto-3-aminopyridines as kcnq2/3 modulators |
| 01/18/2012 | EP2406223A2 Bis aromatic compounds for use as ltc4 synthase inhibitors |
| 01/18/2012 | EP2406222A1 Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors |
| 01/18/2012 | EP2406220A1 Bis aromatic compounds for use as ltc4 synthase inhibitors |
| 01/18/2012 | EP2406218A1 Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer |
| 01/18/2012 | EP2406217A1 Tricyclic heterocyclic derivatives |
| 01/18/2012 | EP2406215A1 Oxo-heterocyclically substituted alkyl carboxylic acids and use thereof |
| 01/18/2012 | EP2406206A1 Tetrahydronaphthalen-2-ol derivatives |
| 01/18/2012 | EP2405973A2 Thiazolopyrimidine modulators as immunosuppressive agents |
| 01/18/2012 | EP2405972A1 Use of rosuvastatin lactols as medicaments |
| 01/18/2012 | EP2405967A2 Implantable device for long-term delivery of drugs |
| 01/18/2012 | EP2405943A2 Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions |
| 01/18/2012 | EP2405942A1 Oral delivery product |
| 01/18/2012 | EP2405941A1 Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment |
| 01/18/2012 | EP2405937A1 Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody |
| 01/18/2012 | EP2405926A1 Cosmetic use of an extract of wolfberry for treating scalp disorders |
| 01/18/2012 | EP2405923A1 Novel coprinus comatus and tremella mesenterica mushroom strains, products and extracts thereof and compositions comprising them |
| 01/18/2012 | EP2405922A1 Nutritional composition inducing a postprandial endocrine response |
| 01/18/2012 | EP2405921A1 Compositions and methods for silencing apolipoprotein c-iii expression |
| 01/18/2012 | EP2405919A2 Treating chronic fatigue syndrome and prolonged qt interval |
| 01/18/2012 | EP2405918A1 Prebiotic oligosaccharides |
| 01/18/2012 | EP2405916A2 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| 01/18/2012 | EP2405915A1 Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| 01/18/2012 | EP2405914A1 Compositions and methods for prophylaxis and treatment of addictions |
| 01/18/2012 | EP2405913A1 Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists |
| 01/18/2012 | EP2405912A2 Method of disease-induced and receptor-mediated stem cell neuroprotection |
| 01/18/2012 | EP2405911A1 Use of atorvastatin lactols as medicaments |
| 01/18/2012 | EP2405910A1 Rosuvastatin and atorvastatin derivatives |
| 01/18/2012 | EP2405909A1 Compositions and methods for elimination of gram-negative bacteria |
| 01/18/2012 | EP2405908A1 Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers |
| 01/18/2012 | EP2405907A1 Treatment of pancreatic cancer |
| 01/18/2012 | EP2405906A2 Method of use of vitamin k as energy enhancer in diverse disease states |
| 01/18/2012 | EP2405905A2 Highly compactable and durable direct compression excipients and excipient systems |
| 01/18/2012 | EP2405903A1 Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof |
| 01/18/2012 | EP2405902A1 Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
| 01/18/2012 | EP2405900A2 A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants |